Fredrik Wiklund, Bright Peak CEO

Ver­sant-backed Bright Peak sets a date to bring its IL-2 in­to the clin­ic — but all eyes are on an IPO af­ter lat­est mega-round drops

Just un­der a year af­ter se­cur­ing its first ven­ture round, a Ver­sant-backed start­up has pulled in a mas­sive Se­ries B haul to cre­ate de­sign­er cy­tokines —and it seems as though CEO Fredrik Wik­lund is keep­ing the S-1 pa­per­work in his back pock­et.

Bright Peak Ther­a­peu­tics un­veiled a $107 mil­lion Se­ries B round on Thurs­day morn­ing, led by RA Cap­i­tal with some help from Ver­sant, Fi­deli­ty Man­age­ment & Re­search Com­pa­ny, In­vus, Qatar In­vest­ment Au­thor­i­ty, Black­Rock, Alexan­dria Ven­ture In­vest­ments and an undis­closed in­vestor.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.